Oramed Pharmaceuticals (ORMP) Net Margin (2016 - 2025)

Oramed Pharmaceuticals' (ORMP) quarterly Net Margin came in at 382.1% in Q1 2025, down 96.14% on a QoQ basis from 194.81% in Q2 2023.

Oramed Pharmaceuticals (ORMP) Net Margin (2016 - 2025) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 8 years of Net Margin data on file, last reported at 382.1% in Q1 2025.

Quarterly Net Margin changed N/A year-over-year to 382.1% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 3760.1% (changed N/A YoY) and the FY2025 annual result came in at 3760.1%, changed N/A from the prior year.
Net Margin slipped to 382.1% in Q1 2025, from 194.81% in the prior quarter.
In the past five years, Net Margin ranged from a high of 194.81% in Q2 2023 to a low of 1565.32% in Q1 2022.
A 4-year average of 920.42% and a median of 928.95% in 2022 frame the typical range for Net Margin.
The widest YoY moves for Net Margin: up 136795 bps in 2023, down 105556 bps in 2023.
Tracing ORMP's Net Margin over 4 years: stood at 822.72% in 2021, then slumped by 57 bps to 1290.71% in 2022, then surged by 85 bps to 194.81% in 2023, then slumped by 96 bps to 382.1% in 2025.
The last three Net Margin figures came in at 382.1% (Q1 2025), 194.81% (Q2 2023), and 509.76% (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Oramed Pharmaceuticals	196.17 Mn	196.17 Mn	-	-

Download Data